XML 51 R32.htm IDEA: XBRL DOCUMENT
v3.19.3

Collaboration and Licensing Revenue (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2019 and 2018.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
ZIOPHARM Oncology, Inc. | $ | 431 |  |  | $ | 4,826 |  |  | $ | 2,130 |  |  | $ | 13,626 |
Ares Trading S.A. | — |  |  | 1,576 |  |  | — |  |  | 7,525 |
Oragenics, Inc. | 231 |  |  | 705 |  |  | 615 |  |  | 867 |
Intrexon T1D Partners, LLC | — |  |  | 368 |  |  | — |  |  | 2,399 |
Intrexon Energy Partners, LLC | 823 |  |  | 1,329 |  |  | 2,596 |  |  | 3,345 |
Intrexon Energy Partners II, LLC | 293 |  |  | 754 |  |  | 1,217 |  |  | 1,685 |
Surterra Holdings, Inc. | 1,022 |  |  | — |  |  | 1,182 |  |  | — |
Genopaver, LLC | 494 |  |  | 689 |  |  | 1,186 |  |  | 3,076 |
Fibrocell Science, Inc. | 402 |  |  | 391 |  |  | 3,247 |  |  | 1,015 |
Persea Bio, LLC | 1,083 |  |  | 199 |  |  | 621 |  |  | 714 |
Harvest start-up entities (1) | 100 |  |  | 2,691 |  |  | 4,862 |  |  | 11,792 |
Other | 1,306 |  |  | 796 |  |  | 3,596 |  |  | 5,578 |
Total | $ | 6,185 |  |  | $ | 14,324 |  |  | $ | 21,252 |  |  | $ | 51,622 |
(1) For the three and nine months ended September 30, 2019 and 2018, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.
Summary of Deferred Revenue | Deferred revenue consists of the following:
| September 30, 2019 |  | December 31, 2018
Collaboration and licensing agreements | $ | 74,431 |  |  | $ | 63,284 |
Prepaid product and service revenues | 3,054 |  |  | 2,933 |
Other | 1,639 |  |  | 3,547 |
Total | $ | 79,124 |  |  | $ | 69,764 |
Current portion of deferred revenue | $ | 12,764 |  |  | $ | 15,554 |
Long-term portion of deferred revenue | 66,360 |  |  | 54,210 |
Total | $ | 79,124 |  |  | $ | 69,764 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2019 and December 31, 2018, including the estimated remaining performance period as of September 30, 2019.
| Average Remaining Performance Period (Years) |  | September 30, 2019 |  | December 31, 2018
ZIOPHARM Oncology, Inc. | 0.0 |  | $ | — |  |  | $ | 1,214 |
Oragenics, Inc. | 4.7 |  | 5,463 |  |  | 5,810 |
Intrexon Energy Partners, LLC | 4.5 |  | 8,362 |  |  | 10,267 |
Intrexon Energy Partners II, LLC | 5.2 |  | 12,843 |  |  | 14,060 |
Surterra Holdings, Inc. | 8.7 |  | 13,987 |  |  | — |
Genopaver, LLC | 4.5 |  | 789 |  |  | 1,175 |
Fibrocell Science, Inc. | 5.1 |  | 18,102 |  |  | 17,519 |
Persea Bio, LLC | 5.3 |  | 3,553 |  |  | 2,697 |
Harvest start-up entities (1) | 5.4 |  | 6,993 |  |  | 7,644 |
Other | 1.7 |  | 4,297 |  |  | 2,898 |
Total |  |  | $ | 74,389 |  |  | $ | 63,284 |
(1) As of September 30, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration